SynthesisJournal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale
Prognostic Significance of Neutrophil-Lymphocyte Ratio in Salivary Gland Neoplasms: A Systematic Review.
Synthesis in Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evaluation of Systemic Inflammatory Markers in Predicting Malignancy in Parotid Gland Tumors.The Laryngoscope · 2026Observational
- SOX-2 and EZH-2 Expression in Primary Epithelial Malignant Salivary Gland Tumors.Medical sciences (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ImportanceSalivary gland tumors (SGTs) are rare and heterogeneous, necessitating improved prognostic tools to optimize patient management.ObjectiveTo evaluate the prognostic value of the neutrophil-to-lymphocyte ratio (NLR) in distinguishing between benign and malignant SGTs, identifying tumor stage, and predicting survival and adverse events.DesignSystematic review conducted according to PRISMA guidelines.SettingPublished clinical studies from tertiary care centers and academic hospitals globally, retrieved from electronic databases (PubMed/MEDLINE, Embase, and Cochrane Library).ParticipantsIncluded studies focused on adult and pediatric patients with histologically-confirmed SGTs. Eligibility criteria encompassed all original research articles reporting NLR values related to diagnosis or prognosis of SGTs.ExposureThe exposure of interest was the NLR, evaluated pretreatment in relation to tumor type (benign vs malignant), tumor stage, survival, and adverse treatment outcomes.Main Outcome MeasuresPrimary outcome: prognostic performance of NLR regarding overall survival and disease stage.ResultsSeventeen original studies were included, with a median cohort size of 123 patients (range: 20-1989). The mean NLR was 2.86 for distinguishing benign versus malignant SGTs, 2.23 for early-stage versus late-stage malignancy, and 3.62 across different malignant histologic subtypes. An NLR below the cutoff value of 2.51 was significantly associated with improved overall survival (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.